Della Makower
Albert Einstein College of Medicine · 131 works · 6,907 citations · h-index 24
Top works
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
- Seroconversion rates following COVID-19 vaccination among patients with cancer
- Progress in adjuvant chemotherapy for breast cancer: an overview
- Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy
- Thymidine Phosphorylase Mediates the Sensitivity of Human Colon Carcinoma Cells to 5-Fluorouracil
- Phase I and Pharmacokinetic Study of the Ribonucleotide Reductase Inhibitor, 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, Administered by 96-Hour Intravenous Continuous Infusion
- Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
- Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.
- Interferon-mediated fatigue
- Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102
- Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
- Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo.
- Evaluation of a National Quality Improvement Collaborative for Improving Cancer Screening
- Systemic Anticancer Therapy and Thromboembolic Outcomes in Hospitalized Patients With Cancer and COVID-19
- TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.
- Occurrence of Myeloma in a Chronic Lymphocytic Leukemia Patient After Response to Differentiation Therapy with Interleukin-4
- Abstract S1-02: PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in post-menopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase inhibitor (AI) therapy
- Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.